{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:18:55Z","timestamp":1788542335611,"version":"build-2803163510"},"reference-count":22,"publisher":"Universa BV","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Immune mediated inflammatory diseases (IMIDs) are a heterogenous group of inflammatory disorders of joint, skin, and gut characterized by both shared and distinct pathological pathways. This complexity has therapeutic implications, as not all IMIDs exhibit responsiveness to available biologicals. Moreover, cases have been documented where patients undergoing biologic therapy experience paradoxical occurrences of either a new IMID or a flare-up of a previously asymptomatic one. Treatment with anti- IL-17a has been approved for ankylosing spondylitis, psoriasis, and psoriatic arthritis, but was not found effective for the treatment of inflammatory bowel disease (IBD). This case series describes four patients with new onset IBD under treatment with an IL-17a inhibitor for a rheumatological or dermatological indication.<\/jats:p>","DOI":"10.51821\/87.3.12874","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T21:57:57Z","timestamp":1730325477000},"page":"413-417","source":"Crossref","is-referenced-by-count":6,"title":["New onset inflammatory bowel disease after initiation of anti-IL-17a treatment: a case series"],"prefix":"10.51821","volume":"87","author":[{"given":"J","family":"Geldof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Truyens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Strubbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Dewitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Glorieus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hoorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Lobaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27062","published-online":{"date-parts":[[2024,10]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"SCHETT G., MCINNES I.B., NEURATH M.F. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. New England Journal of Medicine. 2021;385(7):628-639.","DOI":"10.1056\/nejmra1909094"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"RUDWALEIT M., BAETEN D. Ankylosing spondylitis and bowel disease. Best practice & research Clinical rheumatology. 2006;20(3):451-471.","DOI":"10.1016\/j.berh.2006.03.010"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"EMOND B., ELLIS L.A., CHAKRAVARTY S.D., LADOUCEUR M., LEFEBVRE P. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Current Medical Research and Opinion. 2019;35(10):1751-1759.","DOI":"10.1080\/03007995.2019.1620713"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"ROBINSON D., HACKETT M., WONG J., KIMBALL A.B., COHEN R., BALA M. Co-occurrence and comorbidities in patients with immune- mediated inflammatory disorders: an exploration using US healthcare claims data, 2001\u20132002. Current Medical Research and Opinion. 2006;22(5):989- 1000.","DOI":"10.1185\/030079906x104641"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"BURISCH J., JESS T., EGEBERG A. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark. Clinical Gastroenterology and Hepatology. 2019;17(13):2704- 2712.e2703.","DOI":"10.1016\/j.cgh.2019.03.040"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"LESPESSAILLES E., TOUMI H. Ixekizumab in the treatment of psoriatic arthritis. Immunotherapy. 2021;13(1):19-33.","DOI":"10.2217\/imt-2020-0225"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"WANG J., BHATIA A., CLEVELAND N.K., GUPTA N., DALAL S., RUBIN D.T., SAKURABA A. Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG case reports journal. 2018;5.","DOI":"10.14309\/crj.2018.56"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"FOBELO LOZANO M.J., SERRANO GIM\u00c9NEZ R., CASTRO FERN\u00c1NDEZ M. Emergence of inflammatory bowel disease during treatment with secukinumab. Journal of Crohn\u2019s and Colitis. 2018;12(9):1131-1133.","DOI":"10.1093\/ecco-jcc\/jjy063"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"EHRLICH D., JAMALUDDIN N., PISEGNA J., PADUA D. A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis. Case Reports in Gastrointestinal Medicine. 2018; 9679287.","DOI":"10.1155\/2018\/9679287"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"FUJINO S., ANDOH A., BAMBA S., OGAWA A., HATA K., ARAKI Y., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65-70.","DOI":"10.1136\/gut.52.1.65"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"HUEBER W., SANDS B.E., LEWITZKY S., VANDEMEULEBROECKE M., REINISCH W., HIGGINS P.D., et al. Secukinumab, a human anti- IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693-1700.","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"TARGAN S.R., FEAGAN B., VERMEIRE S., PANACCIONE R., MELMED G.Y., LANDERS C., et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease. Official journal of the American College of Gastroenterology| ACG. 2016;111(11):1599-1607","DOI":"10.1038\/ajg.2016.298"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"SMITH M.K., PAI J., PANACCIONE R., BECK P., FERRAZ J.G., JIJON H. Crohn\u2019s-like disease in a patient exposed to anti-Interleukin-17 blockade(Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC gastroenterology. 2019;19(1):1-6.","DOI":"10.1186\/s12876-019-1067-0"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"PHILIPOSE J., AHMED M., IDICULLA P.S., MULROONEY S.M., GUMASTE V.V. Severe de novo ulcerative colitis following ixekizumab therapy. Case Reports in Gastroenterology. 2018;12(3):617-621.","DOI":"10.1159\/000493922"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"LEE J.S., TATO C.M., JOYCE-SHAIKH B., GULEN M.F., CAYATTE C., CHEN Y., et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity. 2015;43(4):727-738.","DOI":"10.1016\/j.immuni.2015.09.003"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"LI W.-Q., HAN J.-L., CHAN A.T., QURESHI A.A. Psoriasis, psoriatic arthritis and increased risk of incident Crohn\u2019s disease in US women. Annals of the rheumatic diseases. 2013;72(7):1200-1205.","DOI":"10.1136\/annrheumdis-2012-202143"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"VAN DE KERKHOF P.C., GRIFFITHS C.E., REICH K., LEONARDI C.L., BLAUVELT A., TSAI T.-F., et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology. 2016;75(1):83-98. e84.","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"SCHREIBER S., SANDS B., DEODHAR A., BAETEN D., HUANG J., GANDHI K., et al. OP0113 No Increased incidence of inflammatory bowel disease among secukinumab-treated patients with moderate to severe psoriasis, psoriatic arthritis, or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies. BMJ Publishing Group Ltd; 2016.","DOI":"10.1136\/annrheumdis-2016-eular.3684"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"DOS-SANTOS R., ALC\u00c1NTARA I., FERN\u00c1NDEZ D.F., FERN\u00c1NDEZ I.G., CASTRO-SANTAMARIA P., SANCHEZ-WONENBURGER M., et al. AB0942 ANTI-IL17 TREATMENT AND INCIDENCE OF INFLAM- MATORY BOWEL DISEASE: SYSTEMATIC REVIEW AND META- ANALYSIS OF CLINICAL TRIALS. Annals of the Rheumatic Diseases. 2023;82(Suppl 1):1688-1689.","DOI":"10.1136\/annrheumdis-2023-eular.5897"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"LAMBERT J.L.W., SEGAERT S., GHISLAIN P.D., HILLARY T., NIKKELS A., WILLAERT F., et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2). Journal of the European Academy of Dermatology and Venereology. 2020;34(9):1914-1923.","DOI":"10.1111\/jdv.16683"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"NAVARRO-COMP\u00c1N V., PUIG L., VIDAL S., RAM\u00cdREZ J., LLAMAS- VELASCO M., FERN\u00c1NDEZ-CARBALLIDO C., et al. Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Frontiers in Immunology. 2023;14.","DOI":"10.3389\/fimmu.2023.1332177"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"KERSCHBAUMER A., SMOLEN J.S., NASH P., DOERNER T., DOUGADOS M., FLEISCHMANN R., et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. 2020;6(3)","DOI":"10.1136\/rmdopen-2020-001374"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T21:58:00Z","timestamp":1730325480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2188\/New%20onset%20inflammatory%20bowel%20disease%20after%20initiation%20of%20anti-IL-17a%20treatment:a%20case%20series\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10]]},"published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.51821\/87.3.12874","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}